# A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

> **NCT06163170** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 100 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab +/- ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06163170
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-14
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-11-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06163170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06163170, "A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06163170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*